XOMA (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average of $22.95

Shares of XOMA Co. (NASDAQ:XOMA - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $22.95 and traded as high as $25.95. XOMA shares last traded at $25.83, with a volume of 30,619 shares.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $74.00 target price on shares of XOMA in a report on Friday, May 31st. Leerink Partnrs reaffirmed an "outperform" rating on shares of XOMA in a report on Monday, April 29th. Finally, SVB Leerink assumed coverage on shares of XOMA in a research report on Monday, April 29th. They issued an "outperform" rating and a $40.00 price target on the stock.

XOMA Price Performance

The company has a market capitalization of $285.41 million, a price-to-earnings ratio of -6.20 and a beta of 0.85. The company has a debt-to-equity ratio of 1.39, a quick ratio of 9.45 and a current ratio of 9.45. The company has a fifty day simple moving average of $24.95 and a two-hundred day simple moving average of $22.95.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.15). The company had revenue of $1.49 million during the quarter, compared to analyst estimates of $0.96 million. XOMA had a negative net margin of 705.23% and a negative return on equity of 26.00%. As a group, research analysts anticipate that XOMA Co. will post -1.76 earnings per share for the current year.

Institutional Investors Weigh In On XOMA

Institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD purchased a new position in XOMA in the 1st quarter valued at about $212,000. BNP Paribas Financial Markets grew its position in shares of XOMA by 55.6% during the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company's stock valued at $85,000 after buying an additional 1,266 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its stake in XOMA by 25.0% during the third quarter. Stonepine Capital Management LLC now owns 436,602 shares of the biotechnology company's stock worth $6,152,000 after acquiring an additional 87,203 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.